Actualités sur Medicale

Suivre
Abonner Medicale
Filtre
  • 20.07.2022 – 15:11

    Abcam plc

    ABCAM PLC First Half Trading Update

    Cambridge, England (ots/PRNewswire) - Abcam plc ("Abcam", "Company", "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following trading update for the six-month period ending 30 June 2022. The Company will release its full results for the six-month period on 12 September 2022. The Group expects to report total revenues for the six-month period of ...

  • 18.07.2022 – 11:00

    Medimap Systems Inc.

    Medimap Announces New Chief Executive Officer

    Vancouver, Bc (ots/PRNewswire) - CEO Thomas Jankowski intends to expand company's global reach Medimap has officially named Thomas Jankowski as the company's new chief executive officer replacing Blake Adam, the company's founder and former CEO, who has joined Medimap's board of directors. Mr. Jankowski is an innovative digital marketing executive with extensive management and hands-on experience in technology, fintech ...

  • 13.07.2022 – 19:20

    INFOSYS

    Infosys to Acquire Life Sciences Consulting and Technology Leader, BASE life science

    Bengaluru, India and Copenhagen, Denmark (ots/PRNewswire) - Acquisition to deepen life sciences domain capabilities and strengthen footprint across Europe Infosys (NSE, BSE, NYSE: INFY) a global leader in next-generation digital services and consulting, today announced a definitive agreement to acquire BASE life science, a leading technology and consulting firm in the ...

  • 30.06.2022 – 13:01

    Neuromod Devices Ltd

    Neuromod Publishes Results of Second Large Scale Clinical Trial for Tinnitus in Top-Tier Scientific Journal, Shows Greater Improvement of Symptoms

    Dublin (ots/PRNewswire) - - Second large-scale trial shows greater reduction in tinnitus symptom severity using bimodal neuromodulation device, Lenire® - 91% of treatment compliant participants experienced improvement in tinnitus symptoms that sustained 12 months after treatment - 87.8% said they would recommend ...

  • 28.06.2022 – 07:00

    Firmenich

    DSM-Firmenich update on public exchange offer process

    Heerlen, Netherlands and Geneva (ots/PRNewswire) - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. NOT FOR GENERAL RELEASE IN THE UNITED STATES – SEE FURTHER INFORMATION BELOW. This announcement is not for release, publication or distribution, ...

  • 27.06.2022 – 08:01

    Abcam plc

    Abcam: Appointment of Vice President of Investor Relations

    Cambridge, England (ots/PRNewswire) - Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations. Tommy, who will be based in our Waltham, MA office, has over 20 years' experience in the life sciences sector, largely focused in the area of research tools. He joins ...

  • 24.06.2022 – 18:19

    Poda Lifestyle and Wellness Ltd.

    PODA Completes Multiparty Sale of Intellectual Property Assets for US$100.5 Million

    Vancouver, Bc (ots/PRNewswire) - PODA HOLDINGS, INC. ("PODA" or the "Company") (CSE: PODA) (‎FSE: 99L) (OTC: PODAF) is pleased to announce that, further to its news release dated May 13, 2022, the Company, together with Ryan Selby and Ryan Karkairan (the ‎‎"Owners"), has completed the sale of substantially all of the assets and properties ‎used in the Company's ...

  • 13.06.2022 – 07:01

    Firmenich

    DSM and Firmenich confirm leadership team for proposed combined company DSM-Firmenich

    Geneva and Heerlen, Netherlands (ots/PRNewswire) - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. NOT FOR GENERAL RELEASE IN THE UNITED STATES – SEE FURTHER INFORMATION BELOW. DSM and ...

  • 09.06.2022 – 08:01

    MC2 Therapeutics

    Professor Lars Iversen joins MC2 Therapeutics as new Chief Medical Officer

    Copenhagen (ots/PRNewswire) - MC2 Therapeutics A/S, a commercial stage pharmaceutical company, has named Lars Iversen, MD, DMSc an esteemed chair professor in dermatology at Aarhus University Hospital and at Aarhus University, its new full-time Chief Medical Officer (CMO) as of October 1st, 2022. Professor Lars Iversen will be a key member of the Executive Team at MC2 ...